DIRS.INFO The most relevant business & tech news

☆ The one sector of the stock market that is cheap with upside today
▼ + stars: | 2024-09-29 | by ( Karen Firestone | ) www.cnbc.com time to read: +5 min

The table and chart below illustrate some characteristics of the biopharma stocks. The average price/earnings multiple for the group, using 2025 estimates, is 12.7 times versus 20.6 times for the S & P 500. A major knock on the biopharma group is the limited productivity from their extremely expensive research efforts, other than obesity drugs, over the past twenty-five years. The technology using AI might not be ready yet, particularly related to the complex biology of the human body. Complex programs exist already, such as AlphaFold, which predicts the structure of three-dimensional compounds using data on protein sequences.

Persons: Bristol Myers, Amgen, Eli Lilly, Lilly, Johnson Organizations: CNBC, Merck, Pfizer, Novo Nordisk, JPMorgan Locations: Bristol

☆ We're raising our price target on Danaher stock as it sheds a major overhang
▼ + stars: | 2024-07-23 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

That improvement in the bioprocessing end market is super important because it has been a huge overhang for Danaher shares, and the life sciences space in general. We were concerned about the bioprocessing market after rival Sartorius cut its guidance last week. The management team has effectively navigated the bioprocessing slowdown better than others and kept expectations managed — a big reason we've stuck by the stock during a difficult few quarters. Based on these strong results and the improving bioprocessing market, we are raising our price target to $295 from $280 and reiterating our 1 rating. All three operating segments are expected to post sales decline rates in the low single digits.

Persons: Sartorius, Rainer Blair, Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: Club, Revenue, LSEG, Management, Diagnostics, Leica, Beckman Coulter Diagnostics, Cepheid, CNBC, Getty Locations: bioprocessing, Danaher, U.S, Europe, China, Bioprocessing

☆ Hate Apple’s ‘By the Seaside’ alarm tune? You’re not alone
▼ + stars: | 2024-06-23 | by ( Krystal Hur | ) edition.cnn.com time to read: +6 min

Then Apple’s “By the Seaside” alarm sound went off. Moktan chose the jaunty, cheerful tune available as a ringtone and alarm on many of Apple’s devices, thinking that the song’s easygoing melody would make waking up a peaceful experience. Gyaltsen Moktan, a 26-year-old English teacher in Tokyo, says that "By the Seaside" reminds him of horror movie music. Courtesy Gyaltsen Moktan“By the Seaside” is perhaps Apple’s most polarizing alarm and ringtone, evoking comparisons to nails on a chalkboard, the word “moist” and screaming children on a plane. Boston Flake, a 15-year-old high school student in Utah, is in a love-hate relationship with the controversial alarm tune.

Persons: Gyaltsen Moktan, Moktan, ”, Gyaltsen, Carlos Xavier Rodriguez, Levi Hutchins, Antoine Redier, Seth Thomas, Boston, I’ll, ” Apple, Rodriguez, There’s, Rodrigo, Adele, Ryan Meadows, Krystal Roxas, Roxas, “, ” Moktan, Bill Withers, Grover Washington, Jr’s “ Organizations: New, New York CNN, YouTube, University of Michigan School of Music, Theatre & Dance, Boston, Showbiz, CNN Locations: New York, Tokyo, Japan, ”, knocker, Britain, United States, Concord , New Hampshire, French, Utah, San Bruno , California

☆ AstraZeneca targets $80 billion in total revenue by 2030 in 'post-Covid era'
▼ + stars: | 2024-05-21 | by ( Sophie Kiderlin | In | ) www.cnbc.com time to read: +2 min

Costfoto | Future Publishing | Getty ImagesLONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca will focus on its oncology, biopharmaceuticals and rare diseases businesses and expects to release an additional 20 medicines in the next six years. "Many of them have the potential to be $5 billion drugs," Sarin noted. A company statement detailed that this revenue figure could be hit annually for many of the new medicines in peak years. "For the entire market to get replaced it will take time, but we think we have the technology today to start replacing them," Sarin told CNBC.

Persons: CNBC's Arabile Gumede Organizations: Astrazeneca, Artificial Intelligence, — Pharmaceutical, AstraZeneca, CNBC, U.S . FDA, Pharmaceuticals, Investments Locations: Shanghai, China, Europe, London, Singapore

☆ Ozempic and other weight-loss drugs will power the anti-obesity market to 16-fold gains by 2030, Goldman Sachs says
▼ + stars: | 2023-11-04 | by ( George Glover | ) www.businessinsider.com time to read: +3 min

The anti-obesity market could become a $100 billion industry by 2030, Goldman Sachs predicts. The rise of GLP-1 weight loss drugs has meant big gains for Novo Nord Nordisk and Eli Lilly. AdvertisementAdvertisementThe anti-obesity market is primed for a massive surge over the next six years, according to Goldman Sachs. Such a gain would push its total valuation from $6 billion to as much as $100 billion. Meanwhile, Barclays and Berenberg have predicted the market's value could climb to $100 billion and $85 billion respectively.

Persons: Goldman Sachs, Eli Lilly, —, they're, Chris Shibutani, Morgan Stanley Organizations: Novo Nord Nordisk, Service, Denmark's Novo Nordisk, Barclays, Berenberg

☆ This biotech developing a cholesterol drug has a chance to triple, RBC predicts
▼ + stars: | 2023-10-30 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

NewAmsterdam Pharma 's latest drug treatment could lead investors to a windfall, according to RBC Capital Markets. Timashev believes obicetrapib, a cholesterol-lowering treatment, "can succeed where others have failed" due to the drug's specific and idiosyncratic properties. Additionally, the drug has a history of success, consistently demonstrating a 40% to 50% LDL reduction in patients. The analyst added that while current use cases for the drug involve lowering cardiovascular events, there's also potential upside for other applications. Specifically, there's a relationship between higher cholesterol levels and Alzheimer's disease, which could be an avenue for NewAmsterdam to explore for future treatment opportunities.

Persons: Leonid Timashev, Timashev, obicetrapib, there's, — CNBC's Michael Bloom Organizations: NewAmsterdam Pharma, RBC Capital Markets

☆ UBS upgrades this biopharma giant with an underappreciated treatment pipeline
▼ + stars: | 2023-10-20 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Investors may not be fully pricing in Merck 's strong treatment pipeline, according to UBS. Analyst Trung Huynh expects that "underappreciated pipeline readouts" will be the primary contributor to multiple expansion for the company. Huynh also noted that investors continue to underestimate the value of two key Merck treatments: Keytruda — used in cancer immunotherapy — and Gardasil, a vaccine targeting HPV. The analyst added that these two treatments and other underappreciated catalysts have all contributed to Merck's above-peer growth profile. The upgrade comes after the Food and Drug Administration approved the use of Keytruda for treatment with "platinum-containing chemotherapy as neoadjuvant treatment " on Monday.

Persons: Trung Huynh, Huynh, —, Michael Bloom Organizations: Merck, UBS, Food and Drug Administration Locations: China

☆ Wells Fargo’s top fourth-quarter trade ideas include a biopharma stock that could rally 60% off a new treatment
▼ + stars: | 2023-10-06 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

As investors approach year-end, Wells Fargo is offering its top high-conviction and catalyst-driven trade ideas for the fourth quarter of 2023. Question marks notwithstanding, analysts at Wells Fargo recently shared their top 10 tactical ideas for the next three months. But the worst could now be over, wrote analyst Derek Archila. APLS YTD mountain APLS YTD chart Within technology, Wells Fargo highlighted Microsoft as a top pick. Wells Fargo also included hotel and casino company Caesars Entertainment and discount retailer Ollie's Bargain Outlet among its top trade ideas for the fourth quarter.

Persons: Derek Archila, Wells, Michael, Matt Akers, Akers, Wells Fargo, — CNBC's Michael Bloom Organizations: Nasdaq, Wells, Microsoft, Aerospace, L3Harris Technologies, Caesars Entertainment Locations: Wells Fargo, 3Q23

☆ AstraZeneca seeks to calm CEO speculation after shares drop
▼ + stars: | 2023-09-11 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. The company initially declined to comment on the Mail on Sunday report, but later issued a statement saying: "We do not comment on market rumours. AstraZeneca shares closed down 3.2% after earlier touching their lowest since July 19. The Times' article focused on the retirement of Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca, which was announced in July. Reporting by Maggie Fick and Samuel Indyk; Editing by Tomasz Janowski and Mark PotterOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Pascal Soriot, Soriot, Mene Pangalos, Pangalos, Pascal, Maggie Fick, Samuel Indyk, Tomasz Janowski, Mark Potter Organizations: AstraZeneca, New York Stock Exchange, REUTERS, Reuters, Times, Thomson Locations: British

☆ AstraZeneca shares fall 4% to 7-1/2 week low
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: +1 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsCompanies AstraZeneca PLC FollowLONDON, Sept 11 (Reuters) - Shares in London-listed drugmaker AstraZeneca (AZN.L) fell more than 4% on Monday, sliding to their lowest since July 19. An AstraZeneca spokesperson declined to comment on the report. Two of the analysts and the shareholder also mentioned that an article published on Monday in Britain's Times newspaper could have affected the shares, though it appeared to contradict the Mail on Sunday report. The Times' article focused on the retirement of Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca, which was announced in July.

Persons: Brendan McDermid, Pascal Soriot, Mene Pangalos, Pangalos, Pascal, Maggie Fick, Samuel Indyk, Amanda Cooper, Tomasz Janowski Organizations: AstraZeneca, New York Stock Exchange, REUTERS, drugmaker's, Reuters, Britain's Times, Times, Thomson Locations: London

☆ Needham makes its top stock picks to beat the market the next 6 months
▼ + stars: | 2023-08-16 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Several companies, ranging from under-the-radar biotech names to major software providers, could still rake in major gains this year, according to analysts from Needham. Investors can look to these names for some potential returns after witnessing a series of market losses this month. Analysts at the firm forecast 17% upside to the stock based on Tuesday's closing price. The company reported a beat on second-quarter earnings in July amid negative sentiment on the sector, analyst Ryan Koontz noted. Still, the analyst expects continued upside on revenue and earnings per share, driven by a strong rural fiber access market.

Persons: Needham, Biopharmaceuticals, Ami Fadia, MongoDB, Mike Cikos, Cikos, Ryan Koontz, — CNBC's Michael Bloom Organizations: Needham, Dow Jones, Nasdaq, Management, Education Locations: 2H23

☆ A biotech hedge fund that counts Yale’s endowment among its clients bought a new stake in this genetic testing company
▼ + stars: | 2023-08-16 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

Founded by brothers Julian and Felix Baker in 2000, the health care hedge fund focuses on biotech and life sciences investing. The biotech stock with a focus on neuroscience has surged more than 84% this year. Baker Bros. doubled down on its bet in Kymera Therapeutics , which it raised by more than 51%. The hedge fund also took new stakes in ImmunoGen , which has more than tripled this year, soaring 216%, and Day One Biopharmaceuticals , which is down by 34%. The hedge fund lowered its exposure to the biotech company, which develops treatments for cancer, by 5%.

Persons: Baker, Tisch, Julian, Felix Baker, Seagen, Yun Li Organizations: Baker Bros, Advisors, Yale, Acadia Pharmaceuticals, Kymera Therapeutics Locations: InVitae, Invitae, Acadia, ImmunoGen

☆ Viking Global slashes Amazon and insurance positions, adds to bets in biotech
▼ + stars: | 2023-08-15 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Ole Andreas Halvorsen's Viking Global hedge fund slashed its holding in Amazon in the second quarter and stepped up bets in biotech, according to the latest 13F filing with the U.S. Securities and Exchange Commission . The so-called Tiger Cub's entirely new positions included a $78 million stake in Alibaba , $6.5 million in C3.ai and $132 million worth of chipmaker Nvidia . Viking Global also cut investments in the CSX railroad nearly 42%. Elsewhere, Viking Global purchased $278 million worth of Netflix stock in the second quarter and opened a $159 million position in shipping giant UPS . Viking Global managed about $24 billion in 13F securities at the end of the second quarter, according to WhaleWisdom.com .

Persons: Ole Andreas Halvorsen's, Halvorsen, Julian Robertson, Jack Dorsey's Block, Phillip Morris, Philip Morris Organizations: Ole Andreas Halvorsen's Viking Global, U.S . Securities, Exchange Commission, Viking Global, Tiger Management, Nvidia, Viking, CSX, TJX, Meta, Netflix, UPS, Chubb Limited, Tenet Healthcare, General Electric, UnitedHealth Group, Constellation Energy, GE Locations: Ole Andreas Halvorsen's Viking, Alibaba, Viking, Progressive

☆ A portfolio manager at a $179 billion asset manager breaks down how he picks stocks that can endure a volatile economy — and shares 6 of his favorite names to buy
▼ + stars: | 2023-06-30 | by ( Lisa Kailai Han | ) www.businessinsider.com time to read: +6 min

Portfolio manager Elias Erickson focuses on finding stocks that can withstand market fluctuations. With the bull market still flourishing, current stock market conditions are a far cry from where they began the year. Coming off last October's market lows, a series of macroeconomic factors have given equities plenty of whiplash this year. "We're trying to buy businesses that will be adaptable to a variety of different macroeconomic environments," Erickson explained to Insider in an interview. Constellation Software, a Canadian-based acquirer of vertical market software, also makes up one of Erickson's largest positions.

Persons: Elias Erickson, Roger Altman, Paul Krugman, Elias Erickson isn't, Erickson, That's, Hermès, they've, Sartorius Organizations: SAP, Constellation Software, Constellation, Mastercard Locations: Canadian, Lonza

HONG KONG, June 27 (Reuters Breakingviews) - A government-led buyout signals more uncertainty ahead for a chip industry grappling with oversupply and geopolitics. The state-backed Japan Investment Corp will take over JSR (4185.T), which makes light-sensitive chemicals vital to manufacturing semiconductors, among other things. In recent years, the conglomerate has pivoted from a low-margin business of selling synthetic rubber used to make tyres to focus on semiconductor materials - primarily photoresists - and biopharmaceuticals. Yet JIC's mandate to boost the country’s global competitiveness and its focus on consolidating industries helps to justify the hefty premium. Either way, the government's focus on elevating national chipmaking champions creates fresh uncertainty for JSR's foreign customers like South Korea's Samsung Electronics (005930.KS) and Taiwan Semiconductor Manufacturing (2330.TW).

Persons: Sharp, Eric Johnson, Una Galani, Thomas Shum Organizations: Reuters, Japan Investment Corp, Renesas Electronics, chipmakers, Samsung Electronics, Taiwan Semiconductor Manufacturing, Japan Investment Corporation, Mizuho Bank, Development Bank of Japan, Thomson Locations: HONG KONG, Tokyo, Taiwan, Japan, United States, South Korea, South

☆ Sales, spins and splits — what are the differences and why do they matter for investors like us?
▼ + stars: | 2023-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +20 min

Investors may get one share in the spun-out entity for every share of the parent company they owned. What's left of J & J will be focused on pharmaceuticals and medical technologies, which were responsible for over 84% of the company's total 2022 revenue of $94.94 billion. It underscores that once free of the parent company tethers a divested company can chart its own destiny. Those priorities may not have necessarily been wrong when considering J & J as the overall enterprise. We believe J & J and Danaher are poised to deliver two more examples.

☆ Here are the 6 stocks we traded at the start of the second quarter — and why
▼ + stars: | 2023-04-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +6 min

But the first week of trading of the second quarter got off to a rocky start, forcing us to recalibrate our approach to the market. But as the week progressed, stocks came under pressure amid signs the labor market is softening, fueling fresh investor fears of a recession. That prompted many investors to dump technology stocks in favor of defensive sectors like health care and consumer staples. We plan to stick with these three oil stocks, given energy prices are likely to move even higher amid ongoing geopolitical turmoil. Thursday We ended the trading week by purchasing this automation-focused industrial giant on weakness.

☆ J&J backs out of RSV vaccine race with rivals Pfizer and GSK
▼ + stars: | 2023-03-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Johnson & Johnson on Wednesday said it's ducking out of the RSV vaccine race, weeks after competitors Pfizer and GSK inched closer to launching the world's first shot against the deadly virus. J&J will stop working on its investigational RSV adult vaccine program and discontinue a pivotal phase three trial testing the shot, the company announced in a press release. Since then, the race to create the world's first RSV vaccine has garnered more attention than ever. A phase two trial on the company's RSV shot found it provided 80% protection against severe RSV infections. Drugmaker Moderna also has its own potential RSV shot, which performed well in clinical trials.

Hong Kong/Seoul CNN —South Korea says it will build an enormous facility to make computer chips in the greater Seoul area, with about $230 billion in investment from memory chip giant Samsung Electronics. “We will build the world’s largest new ‘high-tech system semiconductor cluster’ in the Seoul Metropolitan area based on large-scale private investment of almost 300 trillion Korean won,” he said. An aerial view of Samsung Electronics' chip production plant at Pyeongtaek, South Korea on September 7, 2022. The vast majority of the world’s advanced microchips are made in just two places, Taiwan and South Korea. Taiwan’s industry is larger and more dominant, something South Korea is keen to challenge.

☆ Lab-grown meat could be served up for dinner soon. What does it taste like?
▼ + stars: | 2022-12-19 | by ( Julia Horowitz | ) edition.cnn.com time to read: +11 min

It has a capacity of 600 liters, or 159 gallons, allowing the company to produce 6,000 pounds of cultivated meat per year. Right now, Singapore is alone in allowing the sale of cultivated meat to consumers, having issued a green light in late 2020. Yet delivering on the promise of lab-grown meat won’t just come down to regulators. CNN“The promise of cultivated meat [is] to bring forth a taste and texture component, and to deliver sustainability,” said Gautam Godhwani, managing partner at Good Startup, a Singapore-based venture capital firm that has invested in eight cultivated meat startups. “I think the whole of the cultivated meat industry will go hybrid first,” Ivy Farm’s Dillon said.

☆ Goldman Sachs says this biotech stock can double on treatment against childhood brain tumor
▼ + stars: | 2022-12-05 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Investors looking for exposure to the biotechnology sector should consider buying Day One Biopharmaceuticals , a stock that can more than double from current levels, according to Goldman Sachs. Analyst Andrea Tan initiated coverage on the biotechnology stock with a buy rating, saying positive data in the first quarter on a possible treatment for childhood brain tumors could unlock a multibillion-dollar sales opportunity. Initial reads on tovorafenib, a treatment for pediatric low-grade glioma, have so far been promising, according to the note. Tovorafenib is under evaluation in a clinical trial called FIREFLY-1 for relapsed pLGG, with data expected in the first quarter of 2023. The analyst expects positive topline data from the trial could serve as a catalyst for the stock and "support a path to approval" for the therapy.

☆ Samsung boss Jay Y. Lee to build on late father's legacy
▼ + stars: | 2022-10-27 | by ( Joyce Lee | ) www.reuters.com time to read: +5 min

Lee, 54, has been vice chairman of Samsung Electronics, the crown jewel of South Korea's biggest business conglomerate, since 2012. That is a major business risk for Samsung, which counts both China and the United States as major markets. But Samsung insiders say his quiet, urbane manner disguises a steely determination Lee will need if he is to grow Samsung. As an only son, Lee was groomed by his father to take over the core business of Samsung Group, which his grandfather founded in 1938. Shares in construction affiliate Samsung C&T (028260.KS), in which Lee owns a 18% stake, rose as much as 7.1%.

Hong Kong/Seoul CNN Business —Samsung has appointed Jay Y. Lee, its longtime de facto leader, as executive chairman. It comes just months after Lee, the scion of one of South Korea’s most powerful families, was pardoned for crimes including embezzlement and bribery. The pardon ended a five-year ban on Lee holding a formal position at Samsung. It said revenue had reached 76.8 trillion won (nearly $54 billion) in the third quarter, despite “a challenging business environment,” and still forecast its full-year revenue to surpass that of 2021. Samsung shares ticked up nearly 1% in Seoul on Thursday following the announcements.

☆ Pfizer developed the Covid vaccine with most of its workforce logging in from home – but a company executive says it's time for employees to get back to the office
▼ + stars: | 2022-10-13 | by ( Samantha Delouya | ) www.businessinsider.com time to read: +3 min

Nearly 2 years after developing a vaccine, Pfizer's Angela Hwang said in-person work is essential for workplace culture. Though many worked from home developing the vaccine, Pfizer's culture was "banked" from years of in-person work, she said. Some companies have recently faced backlash for requiring in-person work. Now, nearly two years after Pfizer and other drugmakers introduced effective vaccines against the virus, requiring workers to return to the office doesn't seem as far-fetched. "Remote working is effective for certain kinds of work," she said.

☆ Nou studiu realizat în SUA: Vaccinul AstraZeneca are o eficienţă 100% împotriva bolii severe şi a spitalizării
▼ + stars: | 2021-03-22 | by ( ) www.jurnal.md time to read: +4 min

Sursa foto: lci.frNou studiu realizat în SUA: Vaccinul AstraZeneca are o eficienţă 100% împotriva bolii severe şi a spitalizăriiVaccinul AstraZeneca are o eficienţă de 79% în prevenirea bolii simptomatice şi de 100% împotriva celei severe şi a spitalizării, potrivit unui studiu efectuat în SUA. Rezultatele unui amplu studiu din SUA au arătat că vaccinul împotriva coronavirusului dezvoltat de AstraZeneca şi Universitatea Oxford are o eficienţă de 79% în prevenirea bolilor simptomatice şi de 100% împotriva bolilor severe şi a spitalizării, relatează Mediafax citând CNBC. Prin comparaţie, vaccinul Moderna are o eficacitate mai mare de 94% în prevenirea coronavirusului, iar vaccinul Pfizer-BioNTech s-a dovedit a avea 95% eficienţă. AstraZeneca a declarat luni, într-un comunicat, că un consiliu independent care a analizat vaccinul său nu a identificat probleme de siguranţă legate de acesta. În special, vaccinul Oxford-AstraZeneca a avut o eficienţă de 80% în prevenirea coronavirusului la participanţii cu vârsta de peste 65 de ani.

Persons: AstraZeneca, Ann Falsey Organizations: Universitatea Oxford, Mediafax, Universităţii Locations: SUA, Germania, Franţa, Italia, Spania, Oxford, Europa, Rochester

Search resuls for: "Biopharmaceuticals"

25 mentions found